HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Posttransplant metabolic complications in living-related renal allograft recipients of Kashmir Valley.

AbstractOBJECTIVES:
Renal transplant offers a definitive therapeutic modality for patients with end-stage renal disease; however, 50% to 70% of these patients have graft dysfunction after the transplant. Proactive prevention management of metabolic complications may reduce posttransplant morbidity and mortality in these patients.
MATERIALS AND METHODS:
A retrospective and prospective review of 120 kidney transplant recipients during 5 years' follow-up was performed to analyze the incidence and status of the various metabolic complications after a renal transplant.
RESULTS:
In our study, postrenal transplant diabetes mellitus was seen in 9 of 120 patients (7.5%). The incidence of posttransplant diabetes mellitus was 5% in tacrolimus-treated patients (n=6) compared with 2.5% in cyclosporine-treated patients (n=3). Dyslipidemia, as hypercholesterolemia and hyper-triglyceridemia, was seen in 31 recipients (25.83%). Significant posttransplant hyperlipidemia was documented (P < .05). Further, it was noted that 25 patients who developed hyperlipidemia (20.83%) were taking cyclosporine-based therapy, while 6 were treated with tacrolimus-based therapy (5%; P < .05). However, most subjects with hyperlipidemia had renal graft dysfunction. Posttransplant erythrocytosis affected 9 renal transplant recipients (7.5%) with a mean (±SD) hematocrit of 41.3%±6.7%. A statistically significant correlation was seen between prerenal and postrenal transplant hematocrit by 12 months. Hyperparathyroidism was observed in 1 renal transplant patient (1.25%).
CONCLUSIONS:
On the basis of this study, we conclude that posttransplant diabetes mellitus occurred in 7.5% patients, hypercholesteremia and hyper-triglyceridemia occurred in 25.83% patients, posttransplant erythrocytosis affected 7.5% patients, and hyperparathyroidism occurred in 1 renal transplant patient (1.25%). Moreover, dyslipidemia, contributed to progressive graft dysfunction.
AuthorsIrfan A Shera, Qayser Yousuf, Mushtaq A Mir, Imtiyaz A Wani, M Saleem Najar
JournalExperimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation (Exp Clin Transplant) Vol. 12 Issue 1 Pg. 25-30 (Feb 2014) ISSN: 2146-8427 [Electronic] Turkey
PMID24471720 (Publication Type: Journal Article)
Chemical References
  • Biomarkers
  • Immunosuppressive Agents
Topics
  • Adult
  • Allografts
  • Biomarkers (blood)
  • Diabetes Mellitus (blood, diagnosis, epidemiology)
  • Dyslipidemias (blood, diagnosis, epidemiology)
  • Female
  • Hematocrit
  • Humans
  • Hyperparathyroidism (blood, diagnosis, epidemiology)
  • Immunosuppressive Agents (adverse effects)
  • Incidence
  • India (epidemiology)
  • Kidney Transplantation (adverse effects)
  • Living Donors
  • Male
  • Middle Aged
  • Polycythemia (blood, diagnosis, epidemiology)
  • Prospective Studies
  • Retrospective Studies
  • Time Factors
  • Transplant Recipients
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: